Vol. 6 No. 10 (2026): October
Reimbursement Reviews

Romosozumab (Evenity)

decorative image of the issue cover

Published October 13, 2026

Key Messages

  • Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies.
  • This review assesses romosozumab 105 mg/1.17 mL prefilled syringe for subcutaneous injection.
  • Type of review: Request for Advice
  • Requester: Formulary Working Group
  • Indication under consideration: Osteoporosis